COVID-19 in PID Survey

With the emergence of SARS-CoV-2 and the COVID-19 pandemic, there is an urgent need tounderstand the impact of infection on immunodeficient individuals. Whilst co-morbidities(such as diabetes, cancer, arterial hypertension, heart disease...) have been documentedin people infected with SARS-CoV-2, there is currently no information on the consequencesand outcomes for individuals with primary immunodeficiencies (PID).Following the 1st phase of the survey (launched by Isabelle Meyts (ESID), Nizar Mahlaoui(CEREDIH & IPOPI) and Kate Sullivan with Stuart Tangye (IUIS), that gave an idea of thenumber of affected PID patients and the impact of SARS-CoV-2 and directly focusing onobtaining this top level of information), we are launching the 2nd phase: "COPID19".COPID19 survey is a secured online GDPR compliant platform based in Paris (ImagineInstitute). It has been approved by the Paris-Necker-Enfants malades IRB and EthicsCommittee. However, this retrospective survey is designed for global distribution. Datacan be entered by a health care professional (mostly clinicians) through a personal loginand password.Each documenting person will have access to his/her own patients' data. COPID19 require agreater level of information than the 1st phase. The eCRF will be open to evolutionsdepending on progresses in our knowledge of this pandemic.